Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Public ClinicalTrials.gov record NCT06904274. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH). Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer. Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need. The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone. In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body. The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population. For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA. The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months. Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site. Participants will visit the study clinic: * once before the treatment starts * 3 times with a gap of 3 months between the visits during the treatment * then 1 more time after the treatment ends During the study, the doctors and their study team will: * check participant's health by performing tests such as blood and urine tests * perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time. * take samples of womb (endometrial) lining * ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Study identification
- NCT ID
- NCT06904274
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- BAY865028 Combination Product
- Medroxyprogesterone acetate Drug
Combination Product · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 23, 2025
- Primary completion
- Jun 16, 2026
- Completion
- Jun 16, 2026
- Last update posted
- Jul 29, 2026
2025 – 2026
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Velocity Clinical Research - Phoenix | Phoenix | Arizona | 85006 | — |
| Cornerstone Clinic for Women - Aldersgate | Little Rock | Arkansas | 72205 | — |
| Alliance Clinical West Hills | West Hills | California | 91307 | — |
| Sweet Hope Research Specialty, Inc. - Hialeah | Hialeah | Florida | 33016 | — |
| New Age Medical Research Corp. | Miami | Florida | 33186 | — |
| Entrust Clinical Research | Palmetto Bay | Florida | 33176 | — |
| Emerald Coast Clinical Research | Panama City | Florida | 32405 | — |
| Paramount Research Solutions | College Park Location | Atlanta | Georgia | 30327 | — |
| Office of Dr. Cindy Basinski, LLC | Evansville | Indiana | 47715 | — |
| Velocity Clinical Research - Lafayette | Lafayette | Louisiana | 70508 | — |
| Southern Clinical Research Associates | Metairie | Louisiana | 70001 | — |
| Omni Fertility and Laser Institute | Shreveport | Louisiana | 71118 | — |
| Revive Research Institute - Michigan - Women's Health | Dearborn Heights | Michigan | 48127 | — |
| Bosque Women's Care | Albuquerque, NM | Albuquerque | New Mexico | 87109 | — |
| Unified Women's Clinical Research - Centre OB/GYN | Raleigh | North Carolina | 27607 | — |
| Lyndhurst Clinical Research | Winston-Salem | North Carolina | 27103 | — |
| ClinOhio Research Services, LLC. | Columbus, OH | Columbus | Ohio | 43213 | — |
| OB/GYN Associates of Erie | Erie | Pennsylvania | 16507 | — |
| Chattanooga Medical Research, LLC. | Chattanooga, TN | Chattanooga | Tennessee | 37412 | — |
| Discovery Clinical Trials - Dallas | Dallas | Texas | 75230 | — |
| Biopharma Informatic - West Houston | Houston | Texas | 77043 | — |
| AIH Research- Broadway | Pearland | Texas | 77584 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06904274, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06904274 live on ClinicalTrials.gov.